News
Menu
- Home
- Company
- Products
- Technology
- Investors
-
News
-
Latest News
- 8mg Higher Dose SCIB1 Study On Track
- Moditope Patent Published
- SCIB1 Granted FDA Orphan Drug Status
- Nottingham Technology Grant
- ImmunoBody technology used in prostate cancer protein discovery
- DNA ImmunoBody Patent Granted in Japan
- New data for SCIB1 in metastatic melanoma
- Extension to Ichor Option and Issue of Equity
- Notice of AGM
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Investor Day Agenda
- Investor Day
- DNA IB Patent in Australia
- Frankfurt Listing
- SCIB1 8mg Study Update
- Scancell welcomes new study in The Journal of Clinical Investigation
- ImmunoBody Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update – Higher Dose Allowed in Phase 1/2 Trial
- Update on SCIB1 Phase 1/2 clinical trial
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB Trial Update - Approval to dose patients for up to 5 years
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1: Patent Awarded
- SCIB1: Safety Review and Dose Escalation
- Scancell develops new vaccine for the treatment of lung cancer
- Change of Board Structure
- SCIB1: Safety Review and Dose Escalation 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Appointment of COO
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Admission to PLUS and Start of Trading
- Reports and accounts April 2008
- Scancell sells antibody pipeline to Peptech
- GTC Biotherapeutics and Scancell Collaborate on SC101 Antibody
- Scancell Raises £1.0 Million In Rights Issue
- Scancell Signs New Agreement with Biovation to DeImmunise SC101
- Scancell Secures Exclusive Worldwide Licence Agreement
- Scancell Raises £1.3 Million ($2.34M; €2M) in New Funding Round
- Scancell Appoints Dr Michael Capaldi as CEO
- Scancell, Onyvax and CRT Announce Agreement to Facilitate the Development of "ImmunoBody"
- Scancell and Celltech Announce that they will Collaborate on the Development of Novel Monoclonal
- Scancell and Isu Chemical Announce Collaboration and Licensing Agreement for Scancell's Antibody
- Genmab and Scancell Announce Cancer Antibody Product Collaboration — First Disease Target Identified
- Advances in Cancer Research Webinar
- Collaboration with Karolinska
- Scancell’s SCIB1 ImmunoBody® cancer vaccine being presented at the World Vaccine Congress
- Citrullination – linking cancer and autoimmunity?
- Scancell to present at the 23rd Annual NewsMakers in the Biotech Industry Conference in NYC
- Europe Patent Release
- Commentary: Richard Goodfellow. Why we want to work with patient advocacy groups
- Professor Lindy Durrant included in top 50 Movers and Shakers in BioBusiness 2017
- Scancell to acquire novel platform technology from the University of Nottingham
- Webcasts, Interviews and Media Coverage
- Archived Webcasts and Interviews
-
Latest News
-
News
- Latest News
- Webcasts, Interviews and Media Coverage
-
Regulatory news
- Interim Results for the six months ended 31 October 2014
- Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations
- Holdings in Company - 15th December 2014
- Change of Registered Office
- Results of AGM
- Appointment of Nominated Adviser and Broker
- AGM research and development update highlights progress in both SCIB1 clinical trial and Moditope® platform
- Scancell to Present at the 14th Annual Biotech in Europe Forum
- Notice of AGM
- Scancell to Present at Upcoming Scientific Conferences
- Final Results for the year ended 30 April 2014
- Synergy of SCIB1 with checkpoint inhibitors
- Grant of Options to Director
- DNA ImmunoBody® Patent Granted in United States
- Update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
- Scancell to present latest SCIB1 data at ASCO Annual Meeting
- Directorate Change
- Dr Sally Adams to Join Scancell
- AACR Presentation on SCIB1
- 8mg Higher Dose SCIB1 Study On Track
- Publication of Moditope® Patent
- SCIB1 Granted FDA Orphan Drug Status
- Holdings in Company - 10 February 2014
- Nottingham Technology Grant
- DNA ImmunoBody® Patent Granted in Japan
- Grant of Options to Directors
- New Data for SCIBI in metastatic melanoma
- Unaudited interim results for 6 months ending 31st October 2013
- Extension to Ichor Commercial Option and Issue of Equity
- Results of AGM Nov 2013
- Director Share Dealing
- AGM Notice
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Holdings in Company - 11 October 2013
- DNA IB Patent in Australia
- Holdings in Company
- Notification of Major Interest in Shares
- Result of General Meeting
- Result of Open Offer
- Director Shareholdings
- SCIB1 8mg Study Update
- Final Results for the year ended 30 April 2013
- Proposed Firm Placing and Open Offer and Notice of General Meeting
- Appoints Peter Allen as Non-Executive Director
- Resignation of Director
- ImmunoBody® Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update - Higher does allowed in phase 1/2 trial - 12th Dec 12
- Directorate Change 12 December 2012
- Update on SCIB1 Phase 1/2 clinical trial
- Result of AGM - 7 November 2012
- Annual Report 30 April 2012
- Notice of Results and Share Price Movement
- Holdings in Company - 6 October 2012
- Holdings in Company - 5 October 2012
- Change of Advisors
- Holdings in Company - 10 September 2012
- Holdings in Company - 3 September 2012
- Holdings in Company - 23 August 2012
- Holdings in Company - 20 August 2012
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB1 Trial Update - Approval to dose patients for up to 5 years
- Vesting of Ichor Options
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company - 16 April 2012
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Change of Registered office 29 February 2012
- Interim Results for the six month period to 31 October 2011
- Issue of Equity
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1 : Patent Awarded
- Holdings in Company - 19 August 2011
- Appointment of Director
- SCIB1: Safety Review and Dose Escalation
- Result of AGM and General Meeting
- Final Results for the Year Ended 30 April 2011
- Subdivision of share capital and Placing to raise £1.73 million
- Change of Board Structure
- Scancell develops new vaccine for the treatment of lung cancer
- Appointment of Broker
- Unaudited Interim Results for the six month period to 31st October 2010
- SCIB1: Safety Review and Dose Escalation January 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Issue of Equity - 13 January 2011
- Result of AGM
- AGM Statement
- Appointment of Broker September 2010
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Grant of Options
- Final Results for the year ended 30 April 2010
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences - First Patient Treated
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- ICHOR Medical Systems, Inc Quantification of Share Options under License and Supply Agreement
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Placing
- Placing of New Ordinary Shares
- Result of Open Offer - March 2010
- Director’s Dealings
- Open Offer
- Clinical Trial Application for SCIB1 melanoma vaccine
- Interim Results for the six month period to 31 October 2009
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Result of AGM - November 2009
- Preliminary Results for the Year Ended 30 April 2009
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Change of Advisor - July 2009
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Interim Results for the six month period to 31 October 2008
- Issue of Equity - December 2008
- Notice of Results
- Admission to PLUS and Start of Trading
- Audited Final Results for the Year Ended
- AACR Presentation on Moditope®
- ASCO Release
- asco data release
- Patient recruitment completed for SCIB1 Phase 1/2 clinical trial
- Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®
- ImmunoBody Presentation at Cancer vaccines Conference in London
- Final Results for the year ended 30th April 2015
- PIVAC Conference Presentations
- Scancell strengthens operational and clinical development expertise
- AGM Business and R&D Update
- Scancell to conduct Phase II checkpoint inhibitor combination study with SCIB1 with leading US melanoma specialists
- Key Moditope® paper published in Cancer Research
- Directorate Change 2016
- Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic
- Interim Results 31st October 2015
- Scancell to present at the Biotech Capital Conference
- Placing and Open Offer
- Placing and Open Offer Close
- Collaboration with Karolinska
- Posting of Circular
- Result of the Open Offer
- Result of the open offer 2
- Notification of Major Interest in Shares 2
- Notification of Major Interest in Shares
- Amendment to Options
- SCIB1 Drug Product Supply
- SCIB1 continues to deliver compelling survival data in melanoma
- Publication highlights advantages of Moditope technology platform
- Extension to Ichor Commercial Option
- Appointment of Eurogentec as SCIB1 manufacturer
- Dr Alan J. Lewis appointed as Non-Executive Director
- Final Results for the year ended 30 April 2016
- Scancell preparing SCIB2 for clinical study in lung cancer
- Results of AGM 2016
- Scancell to present at the World Immunotherapy Congress in Basel and at the Biotech and Money Inv€$tival Showcase in London
- SCIB1 Clinical Study Report
- ALCMI - Scancell Collaboration in Lung Cancer
- Scancell to present at the Immuno-Oncology Summit Europe 2017
- Placing raises £5.0 million, Issue of Equity and PDMR shareholding
- Proposed placing to raise up to £5.0 million
- Continued progress on SCIB1 - eight patients reach 5 year survival milestone
- Holdings in Company 01 March 2017
- Holdings in company 19 May 2017
- Holdngs in Company 19 May 2017 (II)
- Holdings in Company 22 May 2017
- Notice of AGM - Amendment
- Research Update - Amendment
- Interim Results January 2017
- Change of Registered Office April 2017
- Oncimmune and Scancell Present Data
- Scancell presents Moditope at International Cancer Immunotherapy Conference 2017
- Final Results for the year ended 30 April 2017
- Scancell appoints Dr Cliff Holloway as Chief Executive Officer
- Scancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into clinical trials
- Results of October 2017 AGM
- Scancell to collaborate with BioNTech
- Announcement of Share Options 1 February 2018
- Scancell shortlisted for Cancer Research UK’s Grand Challenge award
- Moditope European Patent to be granted
- Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients
- Scancell and ISA Pharmaceuticals announce collaboration
- Scancell presents at Calculus Investor Forum
- PolyPeptide Group appointed to manufacture Scancell’s Modi-1-AMPLIVANT® conjugate
- Proposed Placing, Subscription and Open Offer
- Results of the Placing and Subscription
- Result of Open Offer May 2018
- Moditope European Patent Granted
- Archived Webcasts and Interviews
-
News
- Latest News
- Webcasts, Interviews and Media Coverage
-
Regulatory news
- Interim Results for the six months ended 31 October 2014
- Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations
- Holdings in Company - 15th December 2014
- Change of Registered Office
- Results of AGM
- Appointment of Nominated Adviser and Broker
- AGM research and development update highlights progress in both SCIB1 clinical trial and Moditope® platform
- Scancell to Present at the 14th Annual Biotech in Europe Forum
- Notice of AGM
- Scancell to Present at Upcoming Scientific Conferences
- Final Results for the year ended 30 April 2014
- Synergy of SCIB1 with checkpoint inhibitors
- Grant of Options to Director
- DNA ImmunoBody® Patent Granted in United States
- Update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
- Scancell to present latest SCIB1 data at ASCO Annual Meeting
- Directorate Change
- Dr Sally Adams to Join Scancell
- AACR Presentation on SCIB1
- 8mg Higher Dose SCIB1 Study On Track
- Publication of Moditope® Patent
- SCIB1 Granted FDA Orphan Drug Status
- Holdings in Company - 10 February 2014
- Nottingham Technology Grant
- DNA ImmunoBody® Patent Granted in Japan
- Grant of Options to Directors
- New Data for SCIBI in metastatic melanoma
- Unaudited interim results for 6 months ending 31st October 2013
- Extension to Ichor Commercial Option and Issue of Equity
- Results of AGM Nov 2013
- Director Share Dealing
- AGM Notice
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Holdings in Company - 11 October 2013
- DNA IB Patent in Australia
- Holdings in Company
- Notification of Major Interest in Shares
- Result of General Meeting
- Result of Open Offer
- Director Shareholdings
- SCIB1 8mg Study Update
- Final Results for the year ended 30 April 2013
- Proposed Firm Placing and Open Offer and Notice of General Meeting
- Appoints Peter Allen as Non-Executive Director
- Resignation of Director
- ImmunoBody® Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update - Higher does allowed in phase 1/2 trial - 12th Dec 12
- Directorate Change 12 December 2012
- Update on SCIB1 Phase 1/2 clinical trial
- Result of AGM - 7 November 2012
- Annual Report 30 April 2012
- Notice of Results and Share Price Movement
- Holdings in Company - 6 October 2012
- Holdings in Company - 5 October 2012
- Change of Advisors
- Holdings in Company - 10 September 2012
- Holdings in Company - 3 September 2012
- Holdings in Company - 23 August 2012
- Holdings in Company - 20 August 2012
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB1 Trial Update - Approval to dose patients for up to 5 years
- Vesting of Ichor Options
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company - 16 April 2012
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Change of Registered office 29 February 2012
- Interim Results for the six month period to 31 October 2011
- Issue of Equity
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1 : Patent Awarded
- Holdings in Company - 19 August 2011
- Appointment of Director
- SCIB1: Safety Review and Dose Escalation
- Result of AGM and General Meeting
- Final Results for the Year Ended 30 April 2011
- Subdivision of share capital and Placing to raise £1.73 million
- Change of Board Structure
- Scancell develops new vaccine for the treatment of lung cancer
- Appointment of Broker
- Unaudited Interim Results for the six month period to 31st October 2010
- SCIB1: Safety Review and Dose Escalation January 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Issue of Equity - 13 January 2011
- Result of AGM
- AGM Statement
- Appointment of Broker September 2010
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Grant of Options
- Final Results for the year ended 30 April 2010
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences - First Patient Treated
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- ICHOR Medical Systems, Inc Quantification of Share Options under License and Supply Agreement
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Placing
- Placing of New Ordinary Shares
- Result of Open Offer - March 2010
- Director’s Dealings
- Open Offer
- Clinical Trial Application for SCIB1 melanoma vaccine
- Interim Results for the six month period to 31 October 2009
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Result of AGM - November 2009
- Preliminary Results for the Year Ended 30 April 2009
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Change of Advisor - July 2009
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Interim Results for the six month period to 31 October 2008
- Issue of Equity - December 2008
- Notice of Results
- Admission to PLUS and Start of Trading
- Audited Final Results for the Year Ended
- AACR Presentation on Moditope®
- ASCO Release
- asco data release
- Patient recruitment completed for SCIB1 Phase 1/2 clinical trial
- Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®
- ImmunoBody Presentation at Cancer vaccines Conference in London
- Final Results for the year ended 30th April 2015
- PIVAC Conference Presentations
- Scancell strengthens operational and clinical development expertise
- AGM Business and R&D Update
- Scancell to conduct Phase II checkpoint inhibitor combination study with SCIB1 with leading US melanoma specialists
- Key Moditope® paper published in Cancer Research
- Directorate Change 2016
- Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic
- Interim Results 31st October 2015
- Scancell to present at the Biotech Capital Conference
- Placing and Open Offer
- Placing and Open Offer Close
- Collaboration with Karolinska
- Posting of Circular
- Result of the Open Offer
- Result of the open offer 2
- Notification of Major Interest in Shares 2
- Notification of Major Interest in Shares
- Amendment to Options
- SCIB1 Drug Product Supply
- SCIB1 continues to deliver compelling survival data in melanoma
- Publication highlights advantages of Moditope technology platform
- Extension to Ichor Commercial Option
- Appointment of Eurogentec as SCIB1 manufacturer
- Dr Alan J. Lewis appointed as Non-Executive Director
- Final Results for the year ended 30 April 2016
- Scancell preparing SCIB2 for clinical study in lung cancer
- Results of AGM 2016
- Scancell to present at the World Immunotherapy Congress in Basel and at the Biotech and Money Inv€$tival Showcase in London
- SCIB1 Clinical Study Report
- ALCMI - Scancell Collaboration in Lung Cancer
- Scancell to present at the Immuno-Oncology Summit Europe 2017
- Placing raises £5.0 million, Issue of Equity and PDMR shareholding
- Proposed placing to raise up to £5.0 million
- Continued progress on SCIB1 - eight patients reach 5 year survival milestone
- Holdings in Company 01 March 2017
- Holdings in company 19 May 2017
- Holdngs in Company 19 May 2017 (II)
- Holdings in Company 22 May 2017
- Notice of AGM - Amendment
- Research Update - Amendment
- Interim Results January 2017
- Change of Registered Office April 2017
- Oncimmune and Scancell Present Data
- Scancell presents Moditope at International Cancer Immunotherapy Conference 2017
- Final Results for the year ended 30 April 2017
- Scancell appoints Dr Cliff Holloway as Chief Executive Officer
- Scancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into clinical trials
- Results of October 2017 AGM
- Scancell to collaborate with BioNTech
- Announcement of Share Options 1 February 2018
- Scancell shortlisted for Cancer Research UK’s Grand Challenge award
- Moditope European Patent to be granted
- Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients
- Scancell and ISA Pharmaceuticals announce collaboration
- Scancell presents at Calculus Investor Forum
- PolyPeptide Group appointed to manufacture Scancell’s Modi-1-AMPLIVANT® conjugate
- Proposed Placing, Subscription and Open Offer
- Results of the Placing and Subscription
- Result of Open Offer May 2018
- Moditope European Patent Granted
- Archived Webcasts and Interviews
Press coverage
- What I Learned From the CEO of an Immunotherapy Start-Up
- Biotech blockbusters
- Is this the pioneering DNA vaccine we've been waiting for?
- Electric jab in your arm that fights skin cancer
- Finanz und Wirtschaft 5th June 2013
- Finanz und Wirtschaft 12th June 2013
- ECOreporter 14th August 2013
- Scancell And OncoSec looking good with melanoma immunotherapies
- Why checkpoint inhibitors need help June 2014
Webcasts, Interviews and Media Coverage
Scancell receives European patent protection for immunotherapy platform
The patent protects a new class of cancer vaccines rolling off the Moditope platform
Wed, 23 May 2018 05:28:00
Scancell to raise up to £8mln to develop its three main drug candidates
Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.
A placing and subscription at 12 pence a share will account for £6mln of the total.
The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.
Wed, 18 Apr 2018 12:18:00
Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs
In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline
Wed, 18 Apr 2018 13:15:00
News updates
Sign up to our newsletter to stay up to date with Scancell
Privacy & legal notes
© Copyright Scancell Limited 2018
A site by The Unified Theory